Výsledky vyhledávání - "U N, Vaishampayan"

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

Publikováno v: Journal of Clinical Oncology. 34:544-544

544 Background: Sunitinib (SU) and Pazopanib (PZ) have been compared head-to-head in the first-line phase III COMPARZ study in metastatic renal cell carcinoma (mRCC). We compared SU versus PZ, to confirm outcomes and subsequent second-line therapy ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::624c16ced98d2b9b9b5b2c6e2a98b35a
https://doi.org/10.1200/jco.2016.34.2_suppl.544

Zobrazit plný text záznamu

Blastic mantle cell lymphoma associated with Burkitt-type translocation and hypodiploidy

Autor: U N, Vaishampayan, A N, Mohamed, M C, Dugan, R E, Bloom, M, Palutke

Publikováno v: British journal of haematology. 115(1)

Two elderly men with stage IV mantle cell lymphoma (MCL) rapidly developed a leukaemic phase with unusually high blast counts that proved fatal. One lymph node biopsy showed diffuse MCL, the other blastic morphology. In addition to t(11;14), there we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::30a6b6bbed286e2f6e03ada4cfd05125
https://pubmed.ncbi.nlm.nih.gov/11722412

Zobrazit plný text záznamu

External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy

Autor: F. Donskov, Wanling Xie, Christian K. Kollmannsberger, Min-Han Tan, Connor Wells, Lauren C. Harshman, D. Y. Heng, Yulei Wang, G. A. Bjarnason, Toni K. Choueiri, Sun Young Rha, Lori Wood, J. Lebert, U. N. Vaishampayan, Brian I. Rini

Publikováno v: Journal of Clinical Oncology. 29:4560-4560

4560 Background: The Heng et al JCO 2009 prognostic model was developed in the age of VEGF-targeted therapy and this study serves as an external validation while comparing its performance to other models. Methods: 1,028 previously unanalyzed patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea933351fae13ed7ab927658afa4728c
https://doi.org/10.1200/jco.2011.29.15_suppl.4560

Zobrazit plný text záznamu

The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts)

Autor: G. A. Bjarnason, Mhd Yaser Al-Marrawi, Lauren C. Harshman, Lori Wood, Scott North, D. Y. Heng, Toni K. Choueiri, U. N. Vaishampayan, Sun Young Rha, F. Donskov, Christian K. Kollmannsberger, Neeraj Agarwal, Mary J. MacKenzie, Jennifer J. Knox, Min-Han Tan, Brian I. Rini

Publikováno v: Journal of Clinical Oncology. 29:4555-4555

4555 Background: In mRCC pts who fail first-line VEGF-targeted therapy, there are no available randomized data comparing active drugs. Currently, many clinicians choose a second-line VEGF-targeted therapy based on the type of response to first-line V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e919411277df8c9d2aabf18bafdc4f55
https://doi.org/10.1200/jco.2011.29.15_suppl.4555

Zobrazit plný text záznamu

A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer

Autor: T. K. Choueiri, U. N. Vaishampayan, E. Y. Yu, D. I. Quinn, N. M. Hahn, T. E. Hutson, R. W. Ross, J. E. Rosenberg, S. J. Jacobus, P. W. Kantoff

Publikováno v: Journal of Clinical Oncology. 29:LBA239-LBA239

LBA239 Background: Vandetanib (V) is a novel small-molecule inhibitor that targets key signaling pathways in cancer including VEGF and EGF. V in combination with docetaxel (D) was assessed in patients (pts) who received prior platinum-based chemother

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fbc8253e32bd31f14b1a3872c3e754a6
https://doi.org/10.1200/jco.2011.29.7_suppl.lba239

Zobrazit plný text záznamu

The effect of low serum sodium on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration

Autor: U. N. Vaishampayan, Min-Han Tan, Christian K. Kollmannsberger, F. Donskov, Mary J. MacKenzie, Toni K. Choueiri, Fabio A.B. Schutz, D. Y. Heng, Wanling Xie, Lori Wood

Publikováno v: Journal of Clinical Oncology. 29:322-322

322 Background: Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients (pts) treated with immunotherapy (Jeppesen et al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::64bba3ae470d2121055e5d810a119f63
https://doi.org/10.1200/jco.2011.29.7_suppl.322

Zobrazit plný text záznamu

Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy

Autor: Min-Han Tan, F. Donskov, D. Y. Heng, B. I. Rini, Mary J. MacKenzie, Lori Wood, Toni K. Choueiri, Jennifer J. Knox, U. N. Vaishampayan, G. A. Bjarnason

Publikováno v: Journal of Clinical Oncology. 29:305-305

305 Background: A proportion of patients treated with anti-VEGF therapy first line exhibit progressive disease (PD) as best response (per RECIST). The characteristics and outcome of this population are poorly understood. Methods: Data from patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::949b285b582264beadb92595ff130dfc
https://doi.org/10.1200/jco.2011.29.7_suppl.305

Zobrazit plný text záznamu

A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study

Autor: F. Donskov, Toni K. Choueiri, Wanling Xie, Jennifer J. Knox, G. A. Bjarnason, U. N. Vaishampayan, Lori Wood, B. I. Rini, Christian K. Kollmannsberger, Min-Han Tan, D. Y. Heng

Publikováno v: Journal of Clinical Oncology. 28:4523-4523

4523 Background: Outcomes of second-line targeted therapy (TT) after failure of initial anti-VEGF therapy have not been well characterized. Outcome data as well as existing prognostic criteria in this population were evaluated. Methods: Between 2005-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4dc088d2775f001203b0392572277121
https://doi.org/10.1200/jco.2010.28.15_suppl.4523

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání